Sanofi Genzyme is committed to helping your patients navigate each stage of their treatment journey. We offer a range of support services from copay assistance to personalized patient support to address your patients’ unique needs.
Support For Your Patients
CareConnectPSS, personalized support services for patients, represents Sanofi Genzyme’s more than 25-year commitment to supporting the rare disease community. CareConnectPSS is designed to support each patient’s unique journey.
CareConnectPSS support includes:
1-800-745-4447, Option 3
Connect with us online: www.CareConnectPSS.com
EDUCATIONAL EVENTS FOR FABRY PATIENTS AND THEIR FAMILIES
Sanofi Genzyme sponsors and offers educational events for Fabry patients, their families, and friends to learn more about Fabry disease and Fabrazyme. If your patients express interest in learning more, please refer them to our Rare Disease Events website.
Copay assistance program
The CareConnectPSS® Copay Assistance Program helps eligible patients in the United States who are prescribed Fabrazyme pay for their qualifying out-of-pocket drug costs and certain infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including copays, coinsurance, and deductibles.
Patients or their caregivers interested in applying for the CareConnectPSS Copay Assistance Program will need to complete the following application. Download and learn more here.
Not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance programs. Not valid where prohibited by law. Sanofi Genzyme reserves the right to modify or discontinue the programs at any time. Savings may vary depending on patients’ out-of-pocket costs. All program details provided upon registration.
Billing and reimbursement
Treatment with Fabrazyme is a covered benefit under most major insurance plans, as well as Medicare and Medicaid programs. Sanofi Genzyme is committed to working with providers, as well as public and private payers, to help ensure access to treatment for patients who would medically benefit from Fabrazyme.
The Fabry Registry, sponsored and administered by Sanofi Genzyme, is the largest international patient registry database dedicated to Fabry disease. It is led by a group of physicians with extensive experience in managing patients with Fabry disease.
The Fabry Registry enables a better understanding of the variability and progression of Fabry disease in the population as a whole and in women specifically, and to monitor and evaluate long-term treatment effects of Fabrazyme.
The registry also monitors the effect of Fabrazyme on pregnant women and their offspring. Pregnant women and women of childbearing potential should be encouraged to enroll in the Fabry patient registry. Participation is voluntary and may involve long-term follow-up.The registry’s database helps increase the understanding of Fabry disease by:
In addition, physicians may publish their own data or publish analyses on aggregate Registry data.
To register or find out more, please visit www.registryNXT.com